Heron Therapeutics, Inc. (HRTX) SEC Filings & Earnings Calls

License agreement terms not fully disclosed; milestone and royalty payments may be material.

“Company shall pay regulatory milestone payments, sales-based milestone payments, and royalty payments.”

NOL preservation plan extension indicates company has significant tax attributes to protect; no immediate risk.

“Tax Benefit Preservation Plan extended to 2029.”

Patent invalidation risk for CINVANTI

“On June 1, 2026, the U.S. District Court for the District of Delaware issued a decision ... holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid under 35 U.S.C. § 112.” · word for word

Product discontinuation (SUSTOL)

“On June 15, 2026, we submitted a notification to the FDA that SUSTOL will no longer be available for sale as of September 30, 2026.” · word for word

Patent litigation risk on CINVANTI could lead to generic entry, significantly impacting the largest product's revenue.

“following the June 2026 decision of the U.S. District Court for the District of Delaware (the “Court”) regarding certain patents covering CINVANTI®, the Company does not believe it can reliably forecast the timing or terms of potential generic entry with respect to its largest product.” · word for word

Strategic alternatives process creates uncertainty; no timetable or assurance of transaction.

“the Company is considering strategic alternatives as it continues to execute its current plan. The Company has not set a timetable for this process, there can be no assurance that it will result in any transaction” · word for word

Delisting risk due to low share price; potential reverse stock split needed.

“Nasdaq notice of non-compliance with minimum bid price requirement.”

Loss of patent protection for CINVANTI could lead to generic competition and revenue decline.

“Court invalidated key patents; generic NDA filed by Slayback.”

Oncology Revenue Decline

“Total oncology net product sales decreased by $7.5 million or 26.3% during the three months ended March 31, 2026, as compared to the comparable period in 2025.” · word for word

Accumulated Deficit

“We have incurred significant operating losses and negative cash flows from operations and had an accumulated deficit of $1.9 billion as of March 31, 2026.” · word for word

Gross Margin Pressure

“Gross profit for the three months ended March 31, 2026 was 69.4%, compared to 78.3% for the comparable period in 2025.” · word for word

Oncology franchise decline (CINVANTI -20%, SUSTOL wind-down)

“Oncology net revenue decreased 26.3% YoY; SUSTOL being wound down by end of 2026.”

Temporary gross margin pressure from higher-cost inventory

“expect temporary gross margin pressure to normalize as we work through higher-cost CINVANTI inventory over the next two quarters.” · word for word

NOL impairment risk

“The federal NOL carryforwards consist of $541.7 million generated before January 1, 2018, which began to expire in 2025, and $793.9 million that can be carried forward indefinitely, but are subject to the 80% taxable income limitation.” · word for word

Ownership change risk

“the beneficial ownership of the Company’s common stock...held by certain of the Company’s existing investors, has increased, which has increased the risk of an ownership change under Section 382 of the Internal Revenue Code” · word for word

Potential retention risk if executives leave; enhanced severance could be costly.

“Enhanced severance payments and equity acceleration in change-in-control scenarios.”

Oncology franchise revenue decline of 7.8% YoY, driven by SUSTOL (-39.9%) and CINVANTI (-3.3%).

“Oncology $105,261k vs $114,221k, -7.8% decrease”

Dependence on Acute Care franchise for growth; competitive and reimbursement risks.

“Acute Care franchise growth driven by ZYNRELEF and APONVIE; J-Code approvals support reimbursement.”

Patent litigation risk

“While in December 2024, the District Court found that the Company’s CINVANTI patents are valid and would be infringed by Fresenius Kabi’s proposed generic product, this decision is currently pending appeal and there is no guarantee that other similar or future litigation will be resolved in our favor.” · word for word

Debt burden

“As of December 31, 2025, $111.2 million in aggregate principal amount, including accumulated paid-in-kind interest, under the Working Capital Facility Agreement were outstanding... As of December 31, 2025, $35.9 million aggregate principal amount, including accumulated paid-in-kind interest, for the 2031 Convertible Notes was outstanding.” · word for word

Activist stockholder risk

“In August 2025, we entered into a Cooperation Agreement with Rubric Capital Management LP, regarding certain changes to the composition of the Board and other related matters.” · word for word

Preliminary results subject to audit adjustment.

“Preliminary, unaudited net revenue; final results may differ.”

Oncology revenue decline due to competition

“Total oncology net product sales decreased 3.4% or $2.8 million during the nine months ended September 30, 2025, as compared to the comparable period in 2024. The decrease was primarily attributable to market competition from branded products and generics.” · word for word

SUSTOL wind-down and potential reintroduction uncertainty

“We intend to wind down commercialization of SUSTOL over the next 12 months while we evaluate potential product updates.” · word for word

High accumulated deficit and net loss

“We have incurred significant operating losses and negative cash flows from operations and had an accumulated deficit of $1.9 billion as of September 30, 2025.” · word for word

Loss on debt extinguishment from refinancing

“The increase in expense is related to the loss on debt extinguishment of $11.3 million and an increase in interest expense as a result of the debt refinancing completed in 2025.” · word for word

Dependence on commercial execution for ZYNRELEF and APONVIE; oncology segment SUSTOL declining

“SUSTOL revenue declined 30.8% YoY; oncology segment overall flat; guidance still wide range.”

Activist investor influence may lead to strategic changes or pressure.

“Cooperation Agreement with Rubric Capital Management LP; director with activist background.”